Pacific Biosciences of California, Inc. Chief Accounting Officer William Meyer filed a Form 4 on November 19, 2026, disclosing the acquisition of 54,945 restricted stock units and a stock option covering 72,309 shares on November 17, 2026.
Key Highlights
- RSU grant: William Meyer acquired 54,945 restricted stock units at a price of $0 on November 17, 2026, bringing his direct beneficial ownership of common stock to 98,945 shares following the transaction.
- Stock option grant: Meyer also acquired a stock option (right to buy) covering 72,309 shares of common stock, with an exercise price of $1.82 and an expiration date of November 17, 2036.
- RSU vesting schedule: The RSUs will vest in equal annual installments on November 3 of each of 2027, 2028, 2029, and 2030, subject to Meyer's continued status as a service provider.
- Option vesting schedule: The stock option shares will vest in 48 equal monthly installments beginning December 3, 2026, subject to continued service provider status.
- Role: The filing identifies Meyer as Chief Accounting Officer of Pacific Biosciences of California, Inc., traded on NASDAQ:PACB.
Meyer's November 2026 Equity Awards at Pacific Biosciences
According to the Form 4 filed with the SEC on November 19, 2026, William Meyer, Chief Accounting Officer of Pacific Biosciences of California, Inc. (NASDAQ:PACB), received two equity awards on November 17, 2026. The first was a grant of 54,945 restricted stock units (RSUs) at a reported price of $0. Following this acquisition, the filing states Meyer directly beneficially owns 98,945 shares of common stock.
The filing discloses that each RSU represents one share of common stock and will vest in equal annual installments on November 3 of 2027, 2028, 2029, and 2030, contingent on Meyer's continued status as a service provider through each applicable vesting date. The second award is a stock option granting the right to buy 72,309 shares of common stock at an exercise price of $1.82 per share, expiring November 17, 2036. The filing states the option shares will vest in 48 equal monthly installments beginning December 3, 2026, also subject to continued service provider status. The option was acquired at a price of $0 and Meyer directly holds 72,309 derivative securities following the transaction.
The Form 4 was signed by Brett Atkins as attorney-in-fact on behalf of Meyer and filed on November 19, 2026. Both transactions are recorded as acquisitions (transaction code "A") and are reported as directly held securities.
What Was Disclosed
The filing reports two equity awards to Pacific Biosciences' Chief Accounting Officer William Meyer on November 17, 2026: 54,945 RSUs vesting annually through 2030, and a stock option for 72,309 shares at $1.82 vesting monthly over 48 months beginning December 2026.





Please wait processing your request...